Shprecher, David R., DO, MSCI

Languages

  • English
  • Japanese
  • Spanish

Academic Information

  • Departments: Neurology - Adjunct Associate Professor
  • Divisions: Sleep and Movement Disorders

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)

Academic Office Information

  • 632-832-6500
  • 10515 W. Santa Fe Drive
    Sun City, AZ 85351

Academic Bio

David Shprecher, DO Msci has dedicated his career to improving treatment options for individuals with movement disorders. His work as a site investigator has been aimed at improving symptomatic and disease modifying pharmacological therapies for Parkinson's, Huntington's, Tourette sydrome, progressive supranuclear palsy, and tardive dyskinesia. He has maintained an adjunct appointment with the University of Utah in order to complete ongoing clinical trials, a validation study of colon biopsy for enteric alpha-synuclein pathology in Parkinson disease, and an epidemiological study on risk factors for parkinsonism. His primary appointment is now with the Banner Sun Health Research Institute in Sun City, Arizona, in order to participate in clinical-pathological correlation studies in prodromal and manifest neurodegenerative disease. The ultimate goal of this work is to guide the design of neuroprotection trials aimed at delaying or preventing onset of parkinsonian disorders.

David Shprecher, DO Msci has dedicated his career to improving treatment options for individuals with movement disorders including ataxia, dystonia, essential tremor, Huntington disease, multiple system atrophy, progressive supranuclear palsy, tardive dyskinesia, tics and Tourette syndrome, Lewy body dementia and Parkinson disease. This includes use of botulinum toxin injections and deep brain stimulation to treat movement disorders.

He has maintained an adjunct position with the University of Utah for clinical trials. His primary practice is now located at the Cleo Roberts Clinic in Sun City, Arizona.

Education History

Type School Degree
Graduate Training University of Rochester
Clinical Investigation
M.S.
Fellowship University of Rochester
Movement Disorders
Fellow
Residency University of Utah School of Medicine
Neurology
Resident
Internship University of Utah School of Medicine
Internal Medicine
Intern
Professional Medical Lake Erie College of Osteopathic Medicine
Osteopathic Medicine
D.O.
Undergraduate Cornell University College of Arts and Sciences
Biology
B.S.

Selected Publications

Journal Article

  1. Hauser RA, Fernandez HH, Stamler D, Davis MD, Factor SA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE (2019 Feb). 45 Long-term Treatment with Deutetrabenazine Is Associated with Continued Improvement in Tardive Dyskinesia: Results from an Open-label Extension Study. CNS Spectrums, 24(1), 200-201.
  2. Fernandez HH, Stamler D, Davis MD, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Woods SW, LeDoux MS, Shprecher DR, Anderson KE (2019 Feb). 46 Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-label Extension Study. CNS Spectrums, 24(1), 201.
  3. Shprecher D, Zhang N, Halverson M, Savica R (2019 Mar 23). Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based Study.LID - E71 [pii]LID - 10.3390/brainsci9030071 [doi]. Brain Sci, 9(3).
  4. Barrell K, Bureau B, Turcano P, Phillips GD, Anderson JS, Malik A, Shprecher D, Zorn M, Zamrini E, Savica R (2018). High-Order Visual Processing, Visual Symptoms, and Visual Hallucinations: A Possible Symptomatic Progression of Parkinson's Disease. Front Neurol, 9, 999.
  5. Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB, European Huntingtons Disease Network, HuntingtonStudy Group investigators (). Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurol.
  6. Savica R, Beach TG, Hentz JG, Sabbagh MN, Serrano GE, Sue LI, Dugger BN, Shill HA, Driver-Dunckley E, Caviness JN, Mehta SH, Jacobson SA, Belden CM, Davis KJ, Zamrini E, Shprecher DR, Adler CH doi101111ane13028 Epub ahead of print (). Lewy body pathology in Alzheimer's disease: A clinicopathological prospective study. Acta Neurol Scand.
  7. Shprecher DR, Adler CH, Zhang N, Hentz JG, Serrano GE, Dugger BN, Shill HA, Savica R, Caviness JN, Sabbagh MN, Belden CM, Driver-Dunckley E, Mehta SH, Sue LI, Davis KJ, Zamrini E, Beach TG (2018 May 17). Predicting alpha-synuclein pathology by REM sleep behavior disorder diagnosis.LID - S1353-8020(18)30252-9 [pii]LID - 10.1016/j.parkreldis.2018.05.020 [doi]. (Epub ahead of print) Parkinsonism Relat Disord.
  8. Park HK, Ilango S, Charriez CM, Checkoway H, Riley D, Standaert DG, Bordelon Y, Shprecher DR, Reich SG, Hall D, Kluger B, Marras C, Jankovic J, Dubinsky R, Litvan I (2018 Mar). Lifetime exposure to estrogen and progressive supranuclear palsy: Environmental and Genetic PSP study. Mov Disord, 33(3), 468-472.
  9. Schobel SA, Palermo G, Auinger P, Long JD, Ma S, Khwaja OS, Trundell D, Cudkowicz M, Hersch S, Sampaio C, Dorsey ER, Leavitt BR, Kieburtz KD, Sevigny JJ, Langbehn DR, Tabrizi SJ, TRACK-HD, COHORT, CARE-HD, and 2CARE Huntington StudyGroup Investigators (). Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology, 89(24), 2495-2502.
  10. Marras C, Cunningham CR, Hou J, Proudfoot J, Standaert DG, Juncos J, Riley D, Reich SG, Hall D, Kluger B, Bordelon Y, Shprecher DR, Litvan I (2017 Dec 6). Anti-inflammatory drug use and progressive supranuclear palsy.LID - S1353-8020(17)30813-1 [pii]LID - 10.1016/j.parkreldis.2017.11.346 [doi]. (Epub ahead of print) Parkinsonism Relat Disord.
  11. Gerstenecker A, Roberson ED, Schellenberg GD, Standaert DG, Shprecher DR, Kluger BM, Litvan I (2017 Dec). Genetic influences on cognition in progressive supranuclear palsy. Mov Disord, 32(12), 1764-1771.
  12. Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE (2017 May 23). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology, 88(21), 2003-2010.
  13. Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, Reich SG, Hall DA, Kluger B, Shprecher D, Marras C, Jankovic J (2017 Feb). Understanding falls in progressive supranuclear palsy. Parkinsonism Relat Disord, 35, 75-81.
  14. McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, OSuilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, JankovicJ, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, AndersonK, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M, Huntington Study Group 2CARE Investigators and Coordinators (). A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology, Epub Dec 2 2016.
  15. Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, ONeill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (2016 Jul 5). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316(1), 40-50.
  16. Jankovic J, Jimenez-Shahed J, Budman C, Coffey B, Murphy T, Shprecher D, Stamler D (). Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (N Y), 6.
  17. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, ONeill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E (). Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA, 316(1), 40-50.
  18. Litvan I, Lees PS, Cunningham CR, Rai SN, Cambon AC, Standaert DG, Marras C, Juncos J, Riley D, Reich S, Hall D, Kluger B, Bordelon Y, Shprecher DR (2016 May). Environmental and occupational risk factors for progressive supranuclear palsy: Case-control study. Mov Disord, 31(5), 644-52.
  19. Kious BM, Jimenez-Shahed J, Shprecher DR (2016 Oct 3). Treatment-refractory Tourette Syndrome. Prog Neuropsychopharmacol Biol Psychiatry, 70, 227-36.
  20. Brody DM, Litvan I, Warner S, Riley DE, Hall DA, Kluger BM, Shprecher DR, Cunningham CR (2016 May). Relationship between uric acid levels and progressive supranuclear palsy. Mov Disord, 31(5), 663-7.
  21. Shprecher D, Kious B, Himle M (). Advances in Mechanistic Understanding and Treatment Approaches to Tourette Syndrome. Discov Med, 20(111).
  22. Mata IF, Jang Y, Kim CH, Hanna DS, Dorschner MO, Samii A, Agarwal P, Roberts JW, Klepitskaya O, Shprecher DR, Chung KA, Factor SA, Espay AJ, Revilla FJ, Higgins DS, Litvan I, Leverenz JB, Yearout D, Inca-Martinez M, Martinez E, Thompson TR, Cholerton BA, Hu SC, Edwards KL, Kim KS, Zabetian CP (2015 Sep 24). The RAB39B p.G192R mutation causes X-linked dominant Parkinson's disease. Mol Neurodegener, 10(1), 50.
  23. Writing Group for the NINDS Exploratory Trials in Parkinson Disease NET-PDInvestigators, Kieburtz K, Tilley BC, Elm JJ, et al (). Effect of creatine monohydrate on clinical progression in
    patients with Parkinson disease: a randomized clinical trial. JAMA, 313(6), 584-93.
  24. Shprecher D, Rubenstein L, Gannon K, Frank S, Kurlan R (). Temporal Course of the Tourette Syndrome Clinical Triad. Tremor Other Hyperkinet Mov (N Y).
  25. Shprecher D, Schrock L, Himle M (). Neurobehavioral aspects, pathophysiology, and management of Tourette's syndrome. Curr Opin Neurol, 27(4), 484-92.
  26. Shprecher D, Gannon K, Agarwal N, Shi X, Anderson J (). Elucidating the mechanism of tic improvement in Tourette syndrome: a pilot study. Tremor Other Hyperkinet Mov (N Y).
  27. Duff K, Shprecher D, Litvan I, Gerstenecker A, Mast B on behalf of the ENGENE investigators (). Correcting for demographic variables on the modified Telephone Interview for Cognitive Status. Am J Geriatr Psychiatry.
  28. Elm JJ, NINDS NET-PD Investigators (). Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov Disord, 27(12), 1512-21.
  29. Shprecher D, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jacob (). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology. Telemed J E Health.
  30. Dorsey ER, Voss TS, Shprecher DR, Deuel LM, Beck CA, Gardiner IF, Coles MA, Burns RS, Marshall FJ, Biglan KM (2010 Oct 15). A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Mov Disord, 25(13), 2128-35.
  31. Shprecher D, Silberstein H, Kurlan R (). Propriospinal myoclonus due to cord compression in the absence of myelopathy. Mov Disord, 25(8), 1100-1.
  32. Shprecher D, Mehta L (2010). The syndrome of delayed post-hypoxic leukoencephalopathy. NeuroRehabilitation, 26(1), 65-72.
  33. Shprecher D, Kurlan R (2009 Jan 15). The management of tics. Mov Disord, 24(1), 15-24.
  34. Shprecher DR, Flanigan KM, Smith AG, Smith SM, Schenkenberg T, Steffens J (2008 Fall). Clinical and diagnostic features of delayed hypoxic leukoencephalopathy. J Neuropsychiatry Clin Neurosci, 20(4), 473-7.

Review

  1. Lyon G, Shprecher D, Coffey B, Kurlan R (). Tourette’s Disorder. [Review]. Curr Treat Options Neurol, 12(4), 274-286.
  2. Shprecher D, Schwalb J, Kurlan R (2008 Sep). Normal pressure hydrocephalus: diagnosis and treatment. [Review]. Curr Neurol Neurosci Rep, 8(5), 371-6.

Book Chapter

  1. David Shprecher (). Tics and Tourette Syndrome. In Hall, Deborah / Barton, Brandon (Eds.), Non-Parkinsonian Movement Disorders. Wiley & Sons Ltd.
  2. Hayes L, Himle M, Ramanujam K, Shprecher D (). Tourette Syndrome and Other Tic Disorders. In Kapalka G (Ed.), Treating Disruptive Disorders: A Guide to Psychological, Pharmacological, and Combined Therapies. Routledge.
  3. Roger Kurlan and David Shprecher (). Tics and Tourette syndrome. In Néstor Gálvez-Jiménez and Paul Tuite (Eds.), Uncommon Causes of Movement Disorders. Cambridge University Press.
  4. Shprecher D, Kurlan R (In Press). Complex tics. In Komploti K and Verhagen L (Eds.), The Encyclopedia of Movement Disorders. Elsevier.
  5. Shprecher D, Kurlan R (In Press). Simple tics. In Komploti K and Verhagen L (Eds.), The Encyclopedia of Movement Disorders. Elsevier.

Case Report

  1. Jones KB, Allred J, Shprecher D (2017 Apr). Muscle spasms, twitches in arm upon throwing . Dx? J Fam Pract, 66(4), 234-236.
  2. Shprecher D, Grossmann K, Tward J (). Sustained remission of Parkinson disease associated melanoma with immunotherapy. Parkinsonism Relat Disord.
  3. Shprecher D, Sloan C, Sederholm, B (). Neuropsychiatric side effects of cyclobenzaprine. BMJ Case Rep, (5/2/2013).
  4. Shprecher D (). Sensory Trick with Metoclopramide associated Tardive Tremor. BMJ Case Rep.
  5. Shprecher D, Frech T, Chin S, Eskandari R, Steffens J (2008 Nov). Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus, 17(11), 1029-32.

Editorial

  1. Shprecher DR, Majersik JJ (2017 Sep 12). The virtual house call: A 21st-century innovation in the care of patients with Parkinson disease. Neurology, 89(11), 1103-1104.

Letter

  1. Shprecher DR, Derkinderen P (). Parkinson disease: the enteric nervous system spills its guts. [Letter to the editor]. Neurology, 78(9), 683.

Abstract

  1. DR Shprecher, A Intorcia, M Glass, J Curry, J Walker, B Cutler, M Callan, G Serrano, N Zhang, LI Sue, KJ Davis, TG Beach (). Prevalence of REM Sleep Behavior Disorder in Sun City, Arizona [Abstract]. International Parkinson and Movement Disorder Society, 2018 International Congress, Hong Kong, China.
  2. DR Shprecher, M Callan, B Cutler, G Serrano, CH Adler, HA Shill, JN Caviness, MN Sabbagh, CM Belden, E Driver-Dunckley, SH Mehta, LI Sue, KJ Davis, E Zamrini, TG Beach (). Are Lewy bodies associated with sympathetic pathology in dementia? [Abstract]. International Parkinson and Movement Disorder Society, 2018 International Congress, Hong Kong, China.
  3. DR Shprecher, CH Adler, N Zhang, J G Hentz, GE Serrano, BN Dugger, HA Shill, R Savica, JN Caviness, MN Sabbagh, CM Belden, ED Driver-Dunckley, SH Mehta, LI Sue, KJ Davis, E Zamrini, TG Beach (). Predicting Alpha-Synuclein Pathology by REM Sleep Behavior Disorder Diagnosis [Abstract]. International Parkinson and Movement Disorder Society, 2018 International Congress, Hong Kong, China.
  4. R Hauser Movement Disorders Center, H Fernandez Center for Neurological Restoration, Cleveland Clinic, D Stamler Teva Pharmaceutical Industries, M Davis Teva Pharmaceutical Industries, S Factor Emory University School of Medicine, J Jimenez-Shahed Parkinsons Disease Center and Movement Disorders Clinic, W Ondo Methodist Neurological Institute, L Jarskog University of North Carolina School of Medicine, S Woods Yale School of Medicine, M LeDoux Univ of Tennessee Hlth Science CtrNeuro, D Shprecher Banner Sun Health Research Institute, K Anderson Georgetown University (). Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study [Abstract]. American Academy of Neurology, Los Angeles, CA, USA.
  5. H Fernandez Center for Neurological Restoration, Cleveland Clinic, D Stamler Teva Pharmaceutical Industries, M Davis Teva Pharmaceutical Industries, S Factor Emory University School of Medicine, R Hauser Movement Disorders Center, J Jimenez-Shahed Parkinsons Disease Center and Movement Disorders Clinic, W Ondo Methodist Neurological Institute, L Jarskog University of North Carolina School of Medicine, S Woods Yale School of Medicine, M LeDoux University of Tennessee Health Science Center, D Shprecher Banner Sun Health Research Institute, K Anderson Georgetown University (). Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study [Abstract]. American Academy of Neurology, Los Angeles, CA, USA.
  6. C Adler Mayo Clinic Arizona, T Beach Banner Sun Health Research Institute, N Zhang Mayo Clinic Arizona, H Shill Barrow Neurological Institute, E Driver-Dunckley Mayo Clinic Arizona, J Caviness Mayo Clinic Arizona, S Mehta Mayo Clinic, Arizona, M Sabbagh Barrow Neurological Institute, G Serrano Banner Sun Health Research Institute, L Sue Banner Sun Health Research Institute, C Belden Banner Sun Health Research Institute, J Powell Banner Sun Health Research Institute, S Jacobson University of Arizona, E Zamrini Banner Sun Health Research Institute, D Shprecher Banner Sun Health Research Institute, K Davis Banner Sun Health Research Institute, B Dugger University of California San Francisco, J Hentz Mayo Clinic (). Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations [Abstract]. American Academy of Neurology, April 2018, Los Angeles.
  7. Claudia Testa, Mary Edmondson, Pinky Agarwal, Karen Blindauer, Carolyn Gray, Joseph Jankovic, Rajeev Kumar, David Shprecher, Philip Siragusa, Jacquelyn Whaley and Samuel Frank On behalf of the First-HD and ARC-HD Investigators and Coordinators (). Assessment of capacity to consent in a Huntington disease clinical trial: implications for future clinical trial design in neurodegenerative disease populations [Abstract]. Neurology, 8(16), P2.004.
  8. D Shprecher, J Hentz, C Adler, B Dugger, H Shill, E Driver-Dunkley, S Mehta, M Sabbagh, C Belden, R Savica, L Sue, T Beach (). Utility of the Mayo sleep questionnaire in predicting final autopsy diagnosis of alpha- synucleinopathy [Abstract]. Movement Disorders, 31(S2).
  9. D Shprecher, K Gannon, M Halverson, R Savica (). Parkinsonism risk factors in Salt Lake City, Utah [Abstract]. Movement Disorders, 31(S2).
  10. J Jankovic, J Jimenez-Shahed, C Budman, B Coffey, TK Murphy, D Shprecher, D Stamler (). A pilot study of SD-809 (deutetrabenazine) in tics associated with Tourette syndrome [Abstract]. Movement Disorders, 31(S2).
  11. HH Fernandez, SA Factor, RA Hauser, J Jimenez-Shahed, W Ondo, MS LeDoux, D Shprecher, T Simuni, D Stamler, KE Anderson (). A randomized, double-blind, placebo-controlled trial of deutetrabenazine for the treatment of tardive dyskinesia (ARM-TD.) [Abstract]. Movement Disorders, 31(S2).
  12. BR Bluett, I Litvan, S Cheng, J Juncos, Y Bordelon, DE Riley, D Standaert, SG Reich, DA Hall, B Kluger, D Shprecher, C Marras, J Jankovic (). Understanding, predicting, and preventing falls in progressive supranuclear palsy [Abstract]. Movement Disorders, 31(S2).
  13. Behrang Saminejad, Lilly fagatele, Ka-Ho Wong, Katie Budo, David Shprecher (). Domperidone a Retrospective Review of Tolerability and Safety Profile [Abstract]. American Academy of Neurology, 2016.
  14. Joseph Jankovic, Joohi Jimenez-Shahed, Cathy Budman, Barbara Coffey, Tanya Murphy, David Shprecher, David Stamler (). A Pilot Study of SD-809 (Deutetrabenazine) in Tics Associated with Tourette Syndrome [Abstract]. American Academy of Neurology 2016.
  15. Saminejad, B, Gannon, K, Zorn, M, Shprecher, DR (). Amantadine vs rimantadine in Parkinsonian disorders: A retrospective comparative tolerability study [Abstract]. Movement Disorders 2015;30 Suppl 1 :306.
  16. Kelsey Juster Switlyk MD, Greg Philips, David Shprecher DO, Edward Zamrini MD, Rodolfo Savica MD PhD (). Visual Hallucinations and Visual Misperceptions in Parkinson's Disease: A Retrospective Chart Review [Abstract]. AAN 67th Annual Meeting.
  17. DR Shprecher, L Huynh, P Wall, S Tripp, K Boynton, J Fang, JB Leverenz, J Sonnen (). Colonoscopic screening for enteric nervous system pathology in Parkinson’s disease [Abstract]. 18th International Congress of Parkinson Disease and Movement Disorders.
  18. D Shprecher, J Bautista, A Davis, R Savica (). Understanding risk of parkinsonian disorders [Abstract]. 18th International Congress of Parkinson Disease and Movement Disorders.
  19. Shprecher D, Sloan CT, Sederholm B (). Neuropsychiatric Side Effects of Cyclobenzaprine [Abstract]. Movement Disorders, 28(S1).
  20. Shprecher D, Grossman K, Tward J (). Parkinson Disease Lesion Effect and Melanoma Treatment Response with Ipilimumab and Whole Brain Radiation [Abstract]. Movement Disorders, 28(S1).
  21. Huynh L, Dodiya Hemraj, Kordower Jeffrey, Fang J, Smith AG, Singleton JR, Boynton K, Tietze C, Craig R, Shprecher D (). Colonoscopy Screening for Autonomic Pathology in Parkinson’s Disease [Abstract]. Parkinson Study Group.
  22. Shprecher D, Noyes Katia, Biglan Kevin, Wang Dongwen, Dorsey Ray E, Kurlan Roger, Adams Michael Jacob (). Willingness of Parkinson Disease Patients to Participate in Research Using Internet Based Technology [Abstract]. American Academy of Neurology.
  23. Shprecher, D, Fitts, W, Agarwal, N, Shi, X, Prescott, A, Anderson, J (). Neuroimaging to elucidate the nature and mechanism of tic remission in Tourette syndrome using magnetic resonance imaging [Abstract]. American Academy of Neurology.
  24. Shprecher D and Evans R (). Dysphagia as a presenting symptom of progressive supranuclear palsy [Abstract]. Mov Disord, 25(S2), S508.
  25. Rubenstein L, Shprecher D, Frank S, Kurlan R (2009). Age at remission in patients with Tourette syndrome [Abstract]. Movement Disorders, 24, S501.
  26. Shprecher D, Rubenstein L, Wang D, Kurlan R (March 6th, 2009). Identifying potential subjects for Tourette syndrome clinical research [Abstract]. American Society for Experimental Therapeutics. Arlington, VA.
  27. Dorsey ER, Voss TS, Beck CA, Gardiner IF, Coles MA, Shprecher DR, Deuel LM, Scott J, Burns RS, Marshall FJ, Biglan KM (2008). Group patient visits for Parkinson disease [Abstract]. Movement Disorders, 23(Suppl 1), S345.
  28. Voss TS, Beck CA, Coles MA, Shprecher DR, Deuel LM, Gardiner IF, Burns RS, Marshall FJ, Biglan KM, Dorsey ER (2008). Patient care satisfaction in Parkinson’s disease [Abstract]. Movement Disorders, 23(Suppl 1), S343-S344.
  29. Shprecher DR, Beck CA, Coles MA, Voss TS, Deuel LM, Gardiner IF, Burns RS, Marshall FJ, Biglan KM, Dorsey ER (2008). Support group use by individuals with Parkinson disease [Abstract]. Movement Disorders, 23(Suppl 1), S344.
  30. Shprecher DR, Renner DR, Skalabrin EJ (2006). Moya-Moya associated hemichorea/hemiballism culminating in infarction [Abstract]. Movement Disorders, 21(Suppl 15), S354-355.